Industry / Switzerland

Novartis Restructures

December 2007 | Industry News

Printable version
Bookmark

In response to the tough operating environment currently being experienced by multinational pharmaceutical companies, Swiss giant

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

Nycomed Q310 Results Highlight The Company's Focus On Emerging Markets

Industry / Switzerland BMI View: Nycomed's Q310 results reinforce our view that emerging markets will drive industry growth. The company's sales in Western Europe declined by 5.5% in Q310. Contrastingly, sales in Latin America...

November 2010

Novartis Q310 Results - Outperforming Rivals

Industry / Switzerland BMI View: Novartis will outperform rival pharmaceutical companies over the medium term. The Basel-based firm increasingly appreciates the opportunities presented by emerging markets, which BMI believes...

October 2010

Roche Posts Strong Growth In Emerging Markets In First Nine Months

Industry / Switzerland BMI View: Although developed states will continue to be core revenue streams for major pharmaceutical companies, the negative impact of healthcare reforms and the introduction of government price erosion...

October 2010

Novartis' Gilenya Approved

Industry / Switzerland The US Food and Drug Administration (FDA) has approved Swiss company Novartis' oral multiple sclerosis (MS) treatment Gilenya (fingolimod), a first-line treatment for relapsing forms of MS - the most common...

September 2010

Emerging Markets Drive Roche's Good Half Year Results

Industry / Switzerland BMI Core View: Emerging markets will drive industry growth. The importance of emerging markets to large multinational drugmakers cannot be overstated and BMI's Pharmaceutical Expenditure Model reveals...

July 2010